Maze Therapeutics
Maze Therapeutics is a South San Francisco-based company developing precision medicines for common diseases with large unmet medical needs, focusing on genetically informed therapies for chronic kidney disease and Pompe disease.
Company Overview
Maze Therapeutics, based in South San Francisco, California, is dedicated to developing precision medicines for common diseases with large unmet medical needs. The company focuses on genetically informed therapies, utilizing their proprietary Maze Compass™ platform to create innovative treatments. They aim to halt disease progression and potentially reverse the effects of these conditions by mimicking the effects of rare, naturally occurring protective genetic variants.
Precision Medicine Programs
Maze Therapeutics' primary precision medicine program targets APOL1 kidney disease. They have also announced plans for clinical programs focusing on chronic kidney disease and Pompe disease, with three clinical trials expected to begin in the second half of 2024. Key programs include MZE829 for APOL1-mediated kidney disease, MZE782 for chronic kidney disease, and MZE001 for Pompe disease.
Maze Compass™ Platform
The Maze Compass™ platform is central to Maze Therapeutics' efforts to develop novel precision medicines. This proprietary platform integrates the critical step of variant functionalization into each stage of drug development, helping the company identify and advance treatments that are informed by genetic insights. The platform supports the development of small molecule therapies designed to address the unique needs of patients with common diseases.
MZE001 and Pompe Disease
MZE001 is a novel therapeutic candidate developed by Maze Therapeutics for the treatment of Pompe disease, a rare, inherited disorder caused by mutations in the gene coding for acid alpha-glucosidase (GAA). The U.S. FDA has granted Orphan Drug Designation for this oral substrate reduction therapy. Maze Therapeutics announced an exclusive worldwide license agreement with Shionogi & Co., Ltd. for MZE001, with clinical trials planned to start in the second half of 2024.
Commitment to Kidney Disease
Maze Therapeutics is particularly focused on developing treatments for kidney diseases. Chronic kidney disease affects approximately 37 million individuals in the U.S., and APOL1-mediated kidney disease impacts nearly one million people of West African ancestry in the U.S. alone. The company's pipeline includes MZE829 and MZE782, both targeting forms of kidney disease with significant unmet medical needs. Clinical trials for these programs are expected to commence in the second half of 2024.